GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » Cash Flow from Financing

STE (Steris) Cash Flow from Financing : $-1,572 Mil (TTM As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Steris Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2025, Steris paid $0 Mil more to buy back shares than it received from issuing new shares. It spent $127 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $56 Mil paying cash dividends to shareholders. It received $6 Mil on other financial activities. In all, Steris spent $178 Mil on financial activities for the three months ended in Mar. 2025.


Steris Cash Flow from Financing Historical Data

The historical data trend for Steris's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris Cash Flow from Financing Chart

Steris Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 345.62 115.83 -498.72 -85.19 -1,572.36

Steris Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.77 -998.93 -180.96 -214.40 -178.07

Steris Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Steris's Cash from Financing for the fiscal year that ended in Mar. 2025 is calculated as:

Steris's Cash from Financing for the quarter that ended in Mar. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,572 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steris  (NYSE:STE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Steris's issuance of stock for the three months ended in Mar. 2025 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Steris's repurchase of stock for the three months ended in Mar. 2025 was $-0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Steris's net issuance of debt for the three months ended in Mar. 2025 was $-127 Mil. Steris spent $127 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Steris's net issuance of preferred for the three months ended in Mar. 2025 was $0 Mil. Steris paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Steris's cash flow for dividends for the three months ended in Mar. 2025 was $-56 Mil. Steris spent $56 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Steris's other financing for the three months ended in Mar. 2025 was $6 Mil. Steris received $6 Mil on other financial activities.


Steris Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Steris's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Steris Business Description

Traded in Other Exchanges
Address
5960 Heisley Road, Mentor, OH, USA, 44060
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Executives
Cary L Majors officer: VP, N America Com Operations 5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich director, officer: Sr. Vice Pres., CFO C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Christopher S Holland director ARAMARK CORP, 1101 MARKET ST 29TH FLOOR, PHILADELPHIA PA 19107
Julia Madsen officer: Senior VP, Life Sciences 5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro officer: V.P. & Corporate Treasurer 5960 HEISLEY ROAD, MENTOR OH 44060
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Mohsen Sohi director C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Karen L Burton officer: VP, Controller & CAO 5960 HEISLEY ROAD, MENTOR OH 44060
Jacqueline B Kosecoff director 5960 HEISLEY ROAD, MENTOR OH 44060
Richard C Breeden director 100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
John Adam Zangerle director, officer: Sr. VP, Gen Counsel, and Sec. 5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas officer: SVP and GM, Dental 5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin director C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
David B Lewis director